Page last updated: 2024-10-21
4-aminopyridine and Ischemic Stroke
4-aminopyridine has been researched along with Ischemic Stroke in 1 studies
Ischemic Stroke: Stroke due to BRAIN ISCHEMIA resulting in interruption or reduction of blood flow to a part of the brain. When obstruction is due to a BLOOD CLOT formed within in a cerebral blood vessel it is a thrombotic stroke. When obstruction is formed elsewhere and moved to block a cerebral blood vessel (see CEREBRAL EMBOLISM) it is referred to as embolic stroke. Wake-up stroke refers to ischemic stroke occurring during sleep while cryptogenic stroke refers to ischemic stroke of unknown origin.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "5 mg D-ER, 10 mg D-ER, or placebo, dosed twice-daily for 12 weeks." | 2.94 | A double-blind, randomized, controlled study of two dose strengths of dalfampridine extended release on walking deficits in ischemic stroke. ( Bockbrader, M; El-Feky, WH; Finklestein, SP; Goldstein, M; Kasner, SE; Ning, M; Page, SJ; Roberts, H; Wilson, CA, 2020) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Page, SJ | 1 |
| Kasner, SE | 1 |
| Bockbrader, M | 1 |
| Goldstein, M | 1 |
| Finklestein, SP | 1 |
| Ning, M | 1 |
| El-Feky, WH | 1 |
| Wilson, CA | 1 |
| Roberts, H | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| This is a Multi-center, Double-blind, Three Arm, Parallel Group, Placebo-controlled, Randomized Study Designed to Evaluate the Efficacy, Safety and Tolerability of Dalfampridine.[NCT02271217] | Phase 3 | 377 participants (Actual) | Interventional | 2014-12-31 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Change From Baseline on the Walking Impact Scale (Walk-12) at Week 12 (Key Secondary)
"The Walk-12 is a 12-question questionnaire that asks subjects to rate limitations of their mobility during the preceding two weeks on a 5-point scale (from 1= not at all to 5=extremely). For each visit, the Walk-12 score will be calculated by summing the 12 components and transforming into a scale with a range of 0 to 100. A higher score indicates a greater degree of limitation in walking. A negative change indicates an improvement in walking. 0 = no limitation in mobility to 100 extreme limitation in mobility.~Walk-12 Score = 100 * [(Mean of the 12 items) - 1]/(5-1)" (NCT02271217)
Timeframe: Baseline, week 12
| Intervention | units on a scale (Mean) |
|---|
| Placebo | 45.40 |
| Dalfampridine-ER 7.5 mg | 48.34 |
| Dalfampridine-ER 10mg | 49.26 |
Proportion of Subjects Who Show at Least a 20% Improvement on the Two Minute Walk Test (2MinWT) at Week 12
"The 2MinWT measures the distance a subject can walk in 2 minutes. Participants showing at Least a 20% Improvement on the 2MinWT at 12-weeks are considered Responders." (NCT02271217)
Timeframe: Week 12
| Intervention | participants (Number) |
|---|
| Responder | Non-Responder | Missing |
|---|
| Dalfampridine-ER 10mg | 23 | 90 | 8 |
,| Dalfampridine-ER 7.5 mg | 17 | 96 | 8 |
,| Placebo | 17 | 97 | 12 |
Trials
1 trial available for 4-aminopyridine and Ischemic Stroke